Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Diego, California
- Most recent report
- 8-K, filed Aug 11, 2026
- Incorporated
- Delaware
- Filings on record
- 720 filings
- On EDGAR
- CIK 1370053
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company
Financials 8 of 42
News 8 of 115
- 8-K Shareholder vote results Aug 11, 2026
- 8-K Current report on a material event Jul 30, 2026
- 8-K Significant contract Jun 22, 2026
- 8-K Current report on a material event May 29, 2026
- 8-K Current report on a material event May 21, 2026
- 8-K Quarterly results May 12, 2026
- 8-K Leadership change May 11, 2026
- 8-K/A Current report on a material event, amended Apr 24, 2026
Prospectuses and Registrations 8 of 30
- S-8 Registration statement for an employee plan Aug 6, 2025
- 424B5 Prospectus supplement for an offering Nov 15, 2024
- S-3 Shelf registration statement Nov 5, 2024
- 424B5 Prospectus supplement for an offering Aug 14, 2024
- S-8 Registration statement for an employee plan Aug 5, 2024
- S-8 Registration statement for an employee plan Mar 11, 2024
- S-8 Registration statement for an employee plan Mar 1, 2023
- 424B5 Prospectus supplement for an offering Nov 8, 2022
Proxies 8 of 19
- DEFA14A Extra proxy material Jun 29, 2026
- DEF 14A Proxy statement for a shareholder vote Jun 29, 2026
- DEFA14A Extra proxy material Apr 29, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 29, 2025
- DEFA14A Extra proxy material Apr 24, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 24, 2024
- DEFA14A Extra proxy material Apr 27, 2023
- DEF 14A Proxy statement for a shareholder vote Apr 27, 2023
Ownership 8 of 463
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- 4 Insider reported a trade Aug 7, 2026
- 4 Insider reported a trade Aug 7, 2026
- 144 Notice of a proposed sale of restricted stock Jul 13, 2026
- 144 Notice of a proposed sale of restricted stock Jun 30, 2026
- 144 Notice of a proposed sale of restricted stock Jun 29, 2026
- 144 Notice of a proposed sale of restricted stock Jun 26, 2026
- 144 Notice of a proposed sale of restricted stock Jun 17, 2026
Other 8 of 51
- ARS Annual report sent to shareholders Jun 29, 2026
- ARS Annual report sent to shareholders Apr 29, 2025
- EFFECT Notice that a registration became effective Nov 15, 2024
- CORRESP Reply to SEC staff Nov 13, 2024
- UPLOAD Comment letter from SEC staff Nov 12, 2024
- ARS Annual report sent to shareholders Apr 24, 2024
- ARS Annual report sent to shareholders Apr 27, 2023
- EFFECT Notice that a registration became effective Jan 11, 2022
Everything here comes from Anaptysbio, Inc's own filings on SEC EDGAR. The filing list is rechecked every hour.